摘要
新辅助放疗可降低直肠癌的局部复发率,提高保肛率、生存率及生活质量;在Ⅲ期直肠癌患者中,术前短程放疗比术前常规放疗具有更高的局部复发率;分子标志物联合基因技术可作为预测放疗的敏感性指标.术前常规剂量放疗方案的应用价值明确,放化疗联合的治疗模式具有更好的疗效.多种分子标志物及基因表达谱、基因芯片的发展为直肠癌患者术前制定个体化放疗方案提供了依据.
Neoadjuvant radiotherapy could decrease the local recurrence rate, increase the probability of the anal sphincter preservation, improve survival rate and the quality of patients＂ lives. For stage M patients with rectal cancer, the recurrence rate is higher in short-course radiotherapy compared with conventionally radiotherapy. Molecular markers combined with gene technology can be used as radiosensitivity indicators. Conventional radiotherapy has a definite effect and radiotherapy combined with chemotherapy has better efficacy. The extensive researches of diverse molecular markers,gene expression profiling and gene chips for rectal cancer provide the basis of personalized treatment.
出处
《肿瘤研究与临床》
CAS
2014年第3期212-215,共4页
Cancer Research and Clinic
关键词
直肠肿瘤
新辅助放疗
放疗敏感性
分子标记物
基因表达谱
基因芯片
Rectal neoplasms
Neoadjuvant radiotherapy
Radiosensitivity
Molecular markers
Gene expression profiling
Gene chips
